News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Cenexi is committed to working closely with the ANSM to address the observations
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Subscribe To Our Newsletter & Stay Updated
